Explore our diverse range of medications and therapies.
- Asthma
- COPD
- Lupus
Asthma
Explore our diverse range of medications and therapies.
FASENRA® Safety Information
FASENRA® (benralizumab injection) is indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma.
Consult the FASENRA® Product Monograph for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information, and conditions of clinical use. The Product Monograph is also available by calling AstraZeneca Canada Inc. at 1-800-668-6000.
SYMBICORT® Safety Information
SYMBICORT® TURBUHALER® is indicated for the treatment of asthma in patients 12 years and older with reversible obstructive airways disease.
SYMBICORT® TURBUHALER® can be used according to three different treatment approaches:
- SYMBICORT® TURBUHALER® Anti-inflammatory Reliever Therapy: in patients with mild persistent asthma, SYMBICORT® 200 TURBUHALER® is taken as needed for relief of asthma symptoms when they occur. SYMBICORT® TURBUHALER® has not been evaluated in patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta2-agonist.
- SYMBICORT® TURBUHALER® Anti-inflammatory Reliever plus Maintenance Therapy: in patients with moderate or severe asthma, SYMBICORT® 100 TURBUHALER® or SYMBICORT® 200 TURBUHALER® are taken both as daily maintenance therapy and as needed for relief of asthma symptoms when they occur.
- SYMBICORT® TURBUHALER® Maintenance Therapy: in patients with moderate or severe asthma, SYMBICORT® TURBUHALER® is taken as a fixed-dose daily treatment with a separate short-acting bronchodilator for relief of symptoms when they occur.
Once asthma control is achieved and maintained, the patient should be assessed at regular intervals.
For more information:
Consult the SYMBICORT® TURBUHALER® Product Monograph for important information regarding contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling AstraZeneca Canada Inc. at 1-800-668-6000.
TEZSPIRE® Safety Information
TEZSPIRE® is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma.
TEZSPIRE® is not indicated for relief of acute bronchospasm or status asthmaticus.
Please consult the TEZSPIRE® Product Monograph for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use.
The Product Monograph is also available by calling AstraZeneca Canada Inc. at 1-800-668-6000.
COPD
BREZTRI® Safety Information
BREZTRI® AEROSPHERE® is indicated for the long-term maintenance treatment to reduce exacerbations of COPD and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA.
For more information:
Consult the BREZTRI® AEROSPHERE® Product Monograph for important information regarding contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling AstraZeneca Canada at 1-800-668-6000.
SYMBICORT® Safety Information
SYMBICORT® 200 TURBUHALER® is indicated for:
- The maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate.
For more information:
Consult the SYMBICORT® TURBUHALER® Product Monograph for important information regarding contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling AstraZeneca Canada Inc. at 1-800-668-6000.
Lupus
Explore our diverse range of medications and therapies.
SAPHNELO™ Safety Information
SAPHNELO™ (anifrolumab for injection) is indicated in addition to standard therapy for the treatment of adult patients with active, autoantibody positive systemic lupus erythematosus (SLE).
Please consult the SAPHNELO Product Monograph for clinical use, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-668-6000.
© 2024 AstraZeneca Canada Inc. All rights reserved.
AstraZeneca and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc.
